Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
How do you approach tapering of tocilizumab used for a history of GCA with vision loss?
Related Questions
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
How do you approach worsening memory loss in patients with GCA?
How do you treat IgA vasculitis with gastrointestinal involvement?
Do you always pursue biopsy confirmation before diagnosing IgA vasculitis?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
How would you approach the workup of a female patient who has recurrent sinusitis with polyps (biopsy showed active and chronic inflammation) and myocarditis, but negative ANCA and normal eosinophil counts?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (eg cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (eg neuropathy, palpable purpura, or glomerulonephritis)?
How do you approach treatment of livido vasculitis?
What options are available for patients who require high dose steroids while taking strong CYP4A4 inducers?
